TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 299813

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation and placebo device
Number of subjects: 93
Study: 31150315

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (3 cycles of fluorouracil, leucovorin, and oxaliplatin) before fluorouracil/oxaliplatin CRT (50.4 Gy)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Consolidation chemotherapy after CRT
Number of subjects: 306
Study: 28401821

Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 6693

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 6693
Study: 24730602

Group type: EXPERIMENTAL
Intervention: Anorganic bovine bone (ABB) alone (n = 12)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Anorganic bovine bone (ABB) plus autologous bone (AB) in a 1/1 ratio (n = 7)
Number of subjects: 19
Study: 23868149

Group type: EXPERIMENTAL
Intervention: Chronic cerebrospinal venous insufficiency criteria met by pediatric patients with MS (n = 2) and young adult with pediatric-onset MS (n = 1).
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: MR imaging measures of intracerebral flow in pediatric patients with MS meeting chronic cerebrospinal venous insufficiency criteria (0.85 ± 0.11).
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Demographic and disease characteristics of patients with MS meeting chronic cerebrospinal venous insufficiency criteria (n = 3).
Number of subjects: 65

Group type: COMPARATOR
Intervention: Ultrasound findings in participants.
Number of subjects: 65
Study: 22151937

Group type: EXPERIMENTAL
Intervention: Samphire formulations (0.1% serum, 0.05% cream, serum-cream association, 0.5% silicone oil)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo-preconditioned (silicone oil)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Untreated sites
Number of subjects: 12
Study: 20175799

Group type: EXPERIMENTAL
Intervention: 1000 mg of ascorbic acid and 400 IU of alpha‐tocopherol (treatment group)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Placebo (placebo group)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 75
Study: 16466469

Group type: EXPERIMENTAL
Intervention: ATHENA intervention (8-session program, coach-facilitated, peer-led)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care control condition
Number of subjects: 0
Study: 15239794

Group type: EXPERIMENTAL
Intervention: Radiolucent cushioning pad (MammoPad) used during mammography
Number of subjects: 512

Group type: COMPARATOR
Intervention: Control group (no cushioning pad)
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Radiolucent cushioning pad (MammoPad)
Number of subjects: 512
Study: 12515705

Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy (IMRT)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard Wedged Treatment
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard Treatment
Number of subjects: 300
Study: 9568554

Group type: EXPERIMENTAL
Intervention: Clinical process improvement activities across multiple hospitals and ambulatory physician sites
Number of subjects: 0
Study: 7544845

Group type: EXPERIMENTAL
Intervention: 5 mg finasteride daily for 4 years
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 2230061

Group type: EXPERIMENTAL
Intervention: Zopiclone 7.5 mg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 348534

Group type: EXPERIMENTAL
Intervention: Injectable serenace in dextrose base
Number of subjects: 0

Group type: COMPARATOR
Intervention: Injectable serenace in saline base
Number of subjects: 0
Study: 31828941

Group type: EXPERIMENTAL
Intervention: 12 step program
Number of subjects: 35
Study: 30900436

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 30
Study: 29520385

Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI) after white light cystoscopy (WLC)
Number of subjects: 198

Group type: COMPARATOR
Intervention: White light cystoscopy (WLC) only
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 198
Study: 27027916

Group type: EXPERIMENTAL
Intervention: Post-SMILE corneas
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal eyes
Number of subjects: 80
Study: 24410738

Group type: EXPERIMENTAL
Intervention: SMS text-message intervention (structured programme of clinic appointment, medication pick-up reminders, medication adherence support, and hypertension-related education)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SMS text-message intervention (informational or interactive messages)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (supplemented by infrequent non-hypertension related SMS text-messages)
Number of subjects: 0
Study: 22931079

Group type: EXPERIMENTAL
Intervention: Cherokee Talking Circle (CTC) culturally‐based intervention
Number of subjects: 179

Group type: COMPARATOR
Intervention: Be A Winner Standard Education (SE) condition
Number of subjects: 179
Study: 19668123

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 1051

Group type: COMPARATOR
Intervention: SNRI
Number of subjects: 1051

Group type: EXPERIMENTAL
Intervention: Escitalopram (severe depression subset)
Number of subjects: 1051
Study: 17515293

Group type: EXPERIMENTAL
Intervention: Demoksil 1 g tablet (test preparation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1 g tablet of the originator product (reference preparation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both test and reference preparations
Number of subjects: 0
Study: 15637979

Group type: EXPERIMENTAL
Intervention: IntelliClean System from Sonicare and Crest
Number of subjects: 54

Group type: COMPARATOR
Intervention: Sonicare Elite with conventional toothpaste
Number of subjects: 54
Study: 11441777

Group type: EXPERIMENTAL
Intervention: Evidence-based practice in psychiatry
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical practice guidelines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primary research
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Large, simple randomized trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Access to evidence-based medicine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Collaboration among stakeholders
Number of subjects: 0
Study: 9142380

Group type: EXPERIMENTAL
Intervention: FLEP therapy (5‐fluorouracil 370 mg/m2, leucovorin 30 mg/person, cisplatinum 70 mg/m2, etoposide 70 mg/m2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: FLEP therapy followed by surgery
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Curative surgery after FLEP therapy
Number of subjects: 30
Study: 7535443

Group type: EXPERIMENTAL
Intervention: GM‐/G‐CSF treatment prior to harvest
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated (control)
Number of subjects: 0
Study: 3495732

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole given daily
Number of subjects: 166

Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole given three consecutive days a week
Number of subjects: 166
Study: 31774015

Group type: EXPERIMENTAL
Intervention: Aerobic training for at least 30 months
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Detraining after at least 20 months of aerobic training
Number of subjects: 10

Group type: COMPARATOR
Intervention: Baseline and follow-up measurements
Number of subjects: 10
Study: 29329484

Group type: EXPERIMENTAL
Intervention: Teriparatide 20 μg daily
Number of subjects: 1360

Group type: COMPARATOR
Intervention: Risedronate 35 mg weekly
Number of subjects: 1360
Study: 27545024

Group type: EXPERIMENTAL
Intervention: Fragmentation to dust (group I, n=50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fragmentation into extractable fragments (group II, n=50)
Number of subjects: 100
Study: 24525954

Group type: EXPERIMENTAL
Intervention: Solitaire Flow Restoration with the Intention for Thrombectomy (SWIFT) intervention
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: High baseline ASPECTS (8-10; n=109)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Baseline systolic blood pressure
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Baseline blood glucose
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Failure to achieve Thrombolysis in Cerebral Infarction score of 2b/3 reperfusion
Number of subjects: 139
Study: 22107759

Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIPC)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control (deflated cuff for 30 min)
Number of subjects: 73
Study: 19887114

Group type: EXPERIMENTAL
Intervention: Japanese traditional diet (JTD)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 25
Study: 18413220

Group type: EXPERIMENTAL
Intervention: iopamidol-370 (low osmolar, monomeric)
Number of subjects: 122

Group type: COMPARATOR
Intervention: iodixanol-320 (iso-osmolar, dimeric)
Number of subjects: 122
Study: 15707470

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (CC) 8 mg
Number of subjects: 540

Group type: COMPARATOR
Intervention: Amlodipine (AML) 5 mg
Number of subjects: 540
Study: 12505966

Group type: EXPERIMENTAL
Intervention: Laparoscopic gastroplasty (Group 1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Open laparotomy gastroplasty (Group 2)
Number of subjects: 60
Study: 10639526

Group type: EXPERIMENTAL
Intervention: Nitric oxide (NO) inhalation at 25 ppm with supplemental oxygen at 2 l/min via nasal cannula for 24 hours
Number of subjects: 11

Group type: COMPARATOR
Intervention: Room air with supplemental oxygen at 2 l/min via nasal cannula for 24 hours (control)
Number of subjects: 11
Study: 8672620

Group type: EXPERIMENTAL
Intervention: Imipenem
Number of subjects: 109

Group type: COMPARATOR
Intervention: Other antibiotics
Number of subjects: 109
Study: 1332988

Group type: EXPERIMENTAL
Intervention: Topical application of metronidazole 25% gel
Number of subjects: 24

Group type: COMPARATOR
Intervention: Subgingival scaling
Number of subjects: 24
Study: 2862371

Group type: COMPARATOR
Intervention: Exclusion diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: Unrefined carbohydrate fibre rich diet
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Exclusion diet (in uncontrolled study)
Number of subjects: 20
Study: 30099496

Group type: EXPERIMENTAL
Intervention: ICSI with SrCl2 AOA
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: ICSI with calcimycin AOA
Number of subjects: 343

Group type: COMPARATOR
Intervention: ICSI alone
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: ICSI with SrCl2 AOA (for couples with previous ICSI cycles of low fertilization)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: ICSI with calcimycin AOA (for couples affected by male-factor infertility)
Number of subjects: 343
Study: 27187898

Group type: EXPERIMENTAL
Intervention: Stellate Ganglion Block (SGB)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Stellate Ganglion Block (SGB) - second treatment
Number of subjects: 100
Study: 26458126

Group type: EXPERIMENTAL
Intervention: GOLD A-D classification
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Roflumilast
Number of subjects: 0

Group type: COMPARATOR
Intervention: GOLD I-IV classification
Number of subjects: 0
Study: 23623245

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lacosamide (LCM)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 21146678

Group type: EXPERIMENTAL
Intervention: 600 mg clopidogrel
Number of subjects: 400

Group type: COMPARATOR
Intervention: 300 mg clopidogrel
Number of subjects: 400
Study: 18937864

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with house dust mite allergen
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 251
Study: 16645137

Group type: EXPERIMENTAL
Intervention: Statin users
Number of subjects: 15943
Study: 14740954

Group type: EXPERIMENTAL
Intervention: Candidate live-attenuated dengue virus vaccine
Number of subjects: 0
Study: 11271080

Group type: EXPERIMENTAL
Intervention: Dobutamine infusion starting with an initial dosage of 5 microg x kg x min, increased to a maximum of 10 microg x kg x min.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dobutamine infusion
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Comparison between VO2,IC and VO2,Fick
Number of subjects: 30
Study: 8831306

Group type: EXPERIMENTAL
Intervention: Low mean arterial pressure (50-60 mm Hg) during cardiopulmonary bypass
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: High mean arterial pressure (80-100 mm Hg) during cardiopulmonary bypass
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Atheromatous disease of the descending aorta graded from I to V
Number of subjects: 248
Study: 1482778

Group type: EXPERIMENTAL
Intervention: Educational material on diabetic eye disease and examination findings conveyed to participants and their primary physician
Number of subjects: 619

Group type: COMPARATOR
Intervention: Nonintervention control group (n = 241)
Number of subjects: 619
Study: 3007250

Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg qid
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 30420291

Group type: EXPERIMENTAL
Intervention: Ω‐3 Long‐Chain PolyUnsaturated Fatty Acids (Ω‐3LCPUFA) 2.9 g/d
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sunflower oil (placebo)
Number of subjects: 28
Study: 29394355

Group type: EXPERIMENTAL
Intervention: Rotarix
Number of subjects: 100
Study: 27017514

Group type: EXPERIMENTAL
Intervention: Serelaxin
Number of subjects: 1132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1132
Study: 23913440

Group type: EXPERIMENTAL
Intervention: Hemi-CC7 transfer for hand function (Group 1, n = 20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Total-CC7 transfer (Group 2, n = 20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Simultaneous neurotization on both suprascapular and axillary nerves
Number of subjects: 40
Study: 22773704

Group type: EXPERIMENTAL
Intervention: Trandolapril and delapril (specific dosages not mentioned)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Persistent hyperfiltration
Number of subjects: 600

Group type: COMPARATOR
Intervention: Ameliorated hyperfiltration
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Amelioration of hyperfiltration
Number of subjects: 600
Study: 20433027

Group type: EXPERIMENTAL
Intervention: Dexamethasone sodium phosphate 8 mg (2 mL) intravenous
Number of subjects: 62

Group type: COMPARATOR
Intervention: Saline solution 2 mL intravenous (control)
Number of subjects: 62
Study: 17019380

Group type: EXPERIMENTAL
Intervention: Medical acupuncture
Number of subjects: 103

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 103
Study: 16224674

Group type: EXPERIMENTAL
Intervention: Weak pulsing magnetic fields (daily exposure for 16 minutes over 6 weeks, frequencies of 10, 20, 30, and 200-300 Hz, flux densities from 3.4 to 13.6 microT)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Weak pulsing magnetic fields (after 4 weeks without therapy)
Number of subjects: 71
Study: 11908555

Group type: EXPERIMENTAL
Intervention: ISIS 2302 (0.5 mg/kg)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: ISIS 2302 (1 mg/kg)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: ISIS 2302 (2 mg/kg)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: ISIS 2302 (all doses)
Number of subjects: 43
Study: 10076618

Group type: EXPERIMENTAL
Intervention: D4 lymphadenectomy (group A, n = 35)
Number of subjects: 70

Group type: COMPARATOR
Intervention: D3 lymphadenectomy (group B, n = 35)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: D4 lymphadenectomy (group A)
Number of subjects: 70

Group type: COMPARATOR
Intervention: D3 lymphadenectomy (group B)
Number of subjects: 70
Study: 7552604

Group type: EXPERIMENTAL
Intervention: Glucose 10%
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Glucose 10%/amino acids
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Glucose 10%/amino acids/lipid
Number of subjects: 29

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 29
Study: 1522840

Group type: EXPERIMENTAL
Intervention: High-dose epinephrine (7 mg)
Number of subjects: 650

Group type: COMPARATOR
Intervention: Standard-dose epinephrine (1 mg)
Number of subjects: 650
Study: 6822657

Group type: EXPERIMENTAL
Intervention: Bromocriptine for 14 days
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 5
Study: 30870416

Group type: EXPERIMENTAL
Intervention: Killed whole cell-only oral cholera vaccine (WC-only OCV)
Number of subjects: 50770

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50770
Study: 28838276

Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA)
Number of subjects: 710
Study: 27391795

Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 16
Study: 24368553

Group type: EXPERIMENTAL
Intervention: Endurance training (n = 8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (n = 8)
Number of subjects: 16
Study: 22762978

Group type: COMPARATOR
Intervention: Normal saline (Group C)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Parecoxib 20 mg (Group P(20))
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg (Group P(40))
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Lidocaine 40 mg (Group L)
Number of subjects: 160
Study: 20819323

Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SCIT)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Pharmacotherapy
Number of subjects: 242
Study: 17620811

Group type: EXPERIMENTAL
Intervention: Imageless navigation system
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional implantation instruments
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 200
Study: 16391484

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11965514

Group type: EXPERIMENTAL
Intervention: Olibra fat (0, 2, 4, 6 g) in yoghurt
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control yoghurt (0 g Olibra)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Olibra fat (0, 2, 4, 6 g)
Number of subjects: 50
Study: 10495984

Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olanzapine 12.5-17.5 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 0
Study: 7560247

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study: 1689791

Group type: EXPERIMENTAL
Intervention: iloprost
Number of subjects: 133

Group type: COMPARATOR
Intervention: aspirin
Number of subjects: 133
Study: 7267697

Group type: EXPERIMENTAL
Intervention: diazepam with 120 ml water, preceded by 120 ml of a 50:50 vodka:water mixture
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: diazepam with 120 ml of the vodka mixture, preceded by 120 ml of water
Number of subjects: 6

Group type: COMPARATOR
Intervention: diazepam with 120 ml of water, preceded 30 min before with 120 ml of water (control)
Number of subjects: 6
Study: 30370658

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo cessation
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo noncessation
Number of subjects: 360
Study: 28750582

Group type: EXPERIMENTAL
Intervention: MIN-101 32 mg/day
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: MIN-101 64 mg/day
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: MIN-101 32 mg/day and 64 mg/day
Number of subjects: 244

Group type: COMPARATOR
Intervention: MIN-101 and Placebo
Number of subjects: 244
Study: 27264884

Group type: EXPERIMENTAL
Intervention: Whole body passive hyperthermia treatment (1h in 39.4±0.4°C water)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control resting condition
Number of subjects: 18
Study: 24433977

Group type: EXPERIMENTAL
Intervention: Tyrosine supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22038146

Group type: EXPERIMENTAL
Intervention: Incline plyometrics training (15° incline), 4 weeks, 4 times per week, 8 sets of 10 jumps per session.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Incline plyometrics training (15° incline)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Plane plyometrics training (flat surface)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both groups (Incline and Plane plyometrics)
Number of subjects: 20
Study: 19707579

Group type: EXPERIMENTAL
Intervention: Bar graph of duration of symptoms
Number of subjects: 1760

Group type: COMPARATOR
Intervention: Face icons (happy/sad)
Number of subjects: 1760

Group type: COMPARATOR
Intervention: Bar graph showing proportion of people with symptoms on day three with and without treatment
Number of subjects: 1760

Group type: COMPARATOR
Intervention: Bar graph of average duration of symptoms
Number of subjects: 1760

Group type: COMPARATOR
Intervention: Bar graph of proportion with symptoms on both days three and seven
Number of subjects: 1760
Study: 17314584

Group type: EXPERIMENTAL
Intervention: Valdecoxib 40 mg q.d. (with a second dose on day 1)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Diclofenac 75 mg b.i.d.
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: Valdecoxib
Number of subjects: 340

Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 340
Study: 15357650

Group type: EXPERIMENTAL
Intervention: 600 mg of lamivudine daily
Number of subjects: 10

Group type: COMPARATOR
Intervention: 100 mg of lamivudine daily
Number of subjects: 10